LadRx Corporation Financials
LADX
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 |
|---|---|---|---|---|---|
| General & Administrative | $3 | $4 | $5 | $6 | $6 |
| Research & Development | $1 | $0 | – | – | $1 |
| Total Operating Expenses | $4 | $4 | $5 | $12 | $7 |
| Operating Income | -$4 | -$4 | -$5 | -$12 | -$7 |
| Non-Operating | |||||
| Net Interest Expense | – | – | – | – | $0 |
| Other Non-Operating Income (Expense) | – | $0 | -$0 | -$0 | $0 |
| EBT (Earnings Before Tax) | – | – | – | -$13 | -$7 |
| Income Tax Expense | – | – | – | – | $0 |
| Earnings from Continuing Ops | – | – | – | – | -$7 |
| Net Income | |||||
| Net Income | -$2 | $0 | -$4 | -$13 | -$7 |
| EPS (Basic) | -$3.21 | $0.68 | -$0.11 | -$0.35 | -$0.19 |
| EPS (Diluted) | -$3.21 | $0.68 | -$0.11 | -$0.35 | -$0.19 |
| Weighted Avg Shares (Basic) | 495,092 | 488,392 | 43.4M | 37.6M | 34.7M |
| Weighted Avg Shares (Diluted) | 495,092 | 488,392 | 450,374 | 37.6M | 34.7M |
| Shares Outstanding | 495,092 | 488,392 | 450,374 | 37.6M | 34.7M |
LadRx (LADX) financials: revenue, profit and margins
LadRx (LADX) generated about n/a in revenue and -$2 million in net income over the trailing twelve months, growing at roughly -59.7% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is LadRx profitable?+
LadRx reported about -$2 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is LadRx growing?+
LadRx's revenue has compounded at roughly -59.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside LADX's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 14 May 2025, covering the period ending 31 Mar 2025, as reported to the SEC. Data last refreshed 21 Aug 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with LADX
Spot a number that looks wrong? Check it in LADX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LADX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.